AU2002216610A1 - Secreted and transmembrane polypeptides and nucleic acids encoding the same - Google Patents

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Info

Publication number
AU2002216610A1
AU2002216610A1 AU2002216610A AU2002216610A AU2002216610A1 AU 2002216610 A1 AU2002216610 A1 AU 2002216610A1 AU 2002216610 A AU2002216610 A AU 2002216610A AU 2002216610 A AU2002216610 A AU 2002216610A AU 2002216610 A1 AU2002216610 A1 AU 2002216610A1
Authority
AU
Australia
Prior art keywords
secreted
same
nucleic acids
acids encoding
transmembrane polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002216610A
Other languages
English (en)
Inventor
Kevin P. Baker
Dan L Eaton
Ellen Filvaroff
Sherman Fong
Audrey Goddard
J. Christopher Grimaldi
Austin L. Gurney
Victoria Smith
Jean-Philippe Stephan
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27585542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002216610(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/fr
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/fr
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/fr
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2002216610A1 publication Critical patent/AU2002216610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002216610A 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same Abandoned AU2002216610A1 (en)

Applications Claiming Priority (45)

Application Number Priority Date Filing Date Title
US22989600P 2000-09-01 2000-09-01
US60/229,896 2000-09-01
US23062100P 2000-09-05 2000-09-05
US60/230,621 2000-09-05
US23514700P 2000-09-22 2000-09-22
US60/235,147 2000-09-22
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
AU34346/01 2000-11-10
US26187801P 2001-01-12 2001-01-12
US60/261,878 2001-01-12
US26215001P 2001-01-16 2001-01-16
US26193901P 2001-01-16 2001-01-16
US26191001P 2001-01-16 2001-01-16
US60/261,910 2001-01-16
US60/262,150 2001-01-16
US60/261,939 2001-01-16
US26439501P 2001-01-25 2001-01-25
US60/264,395 2001-01-25
US26642101P 2001-02-02 2001-02-02
US60/266,421 2001-02-02
US26762301P 2001-02-09 2001-02-09
US60/267,623 2001-02-09
AU2001268028 2001-02-28
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US27439901P 2001-03-09 2001-03-09
US60/274,399 2001-03-09
US28098201P 2001-04-03 2001-04-03
US60/280,982 2001-04-03
US28219901P 2001-04-04 2001-04-04
US28212901P 2001-04-04 2001-04-04
US60/282,199 2001-04-04
US60/282,129 2001-04-04
US29058901P 2001-05-09 2001-05-09
US60/290,589 2001-05-09
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
AU2001265019 2001-05-25
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
AU2001265311 2001-06-01
AU2001278852 2001-06-20
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
AU2001273150 2001-06-29
PCT/US2001/021066 WO2002008288A2 (fr) 2000-07-20 2001-06-29 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
AU2001271973 2001-07-09
PCT/US2001/021735 WO2002008284A2 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
PCT/US2001/027099 WO2002024888A2 (fr) 2000-09-01 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci

Publications (1)

Publication Number Publication Date
AU2002216610A1 true AU2002216610A1 (en) 2002-04-02

Family

ID=27585542

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002216610A Abandoned AU2002216610A1 (en) 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1661002A Pending AU1661002A (en) 2000-09-01 2001-09-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU1661002A Pending AU1661002A (en) 2000-09-01 2001-09-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Country Status (5)

Country Link
EP (1) EP1341814A2 (fr)
JP (2) JP4451059B2 (fr)
AU (2) AU2002216610A1 (fr)
CA (2) CA2421056A1 (fr)
WO (1) WO2002024888A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2261335T (pt) 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1250426A2 (fr) * 1999-12-01 2002-10-23 Genentech Inc. Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci
US20040132021A1 (en) * 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
AU2002249948B2 (en) 2001-01-12 2007-08-23 Genetics Institute, Llc Type 2 cytokine receptor and nucleic acids encoding same
ATE464320T1 (de) * 2001-07-19 2010-04-15 Innate Pharma Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
FR2844713A1 (fr) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Nouvelle cible de l'angiogenese et utilisations
WO2004035789A1 (fr) * 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Familles de genes associes a des cancers
MEP2808A (xx) 2003-06-16 2010-02-10 Celltech R & D Inc Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011051271A2 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeur de la prostate et méthodes d'utilisation
WO2011051280A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
EP2383578A1 (fr) * 2010-04-30 2011-11-02 Externautics S.p.A. Marqueur de tumeur et procédés d'utilisation correspondants
EP3195880B1 (fr) 2010-05-14 2019-11-27 Amgen Inc. Formulations d'anticorps anti-sclerostin hautement concentree
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014100740A1 (fr) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anticorps anti-ntb-a et compositions et procédés associés
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO1998039448A2 (fr) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 nouvelles proteines secretees
JP2002512517A (ja) * 1997-03-25 2002-04-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
DE19817557A1 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1210418B1 (fr) * 1999-06-02 2010-08-18 Genentech, Inc. Polypeptides secretes et transmembranaires ainsi que les acides nucleiques codant pour ceux-ci

Also Published As

Publication number Publication date
JP2006223304A (ja) 2006-08-31
CA2421056A1 (fr) 2002-03-28
WO2002024888A2 (fr) 2002-03-28
EP1341814A2 (fr) 2003-09-10
JP2004526412A (ja) 2004-09-02
WO2002024888A3 (fr) 2003-07-03
AU1661002A (en) 2002-04-02
JP4451059B2 (ja) 2010-04-14
CA2632702A1 (fr) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001268028A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001273150A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001265311A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2002216610A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7573000A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2055401A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883700A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883900A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL139686A0 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL188581A0 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999046281A8 (fr) Nouveaux polypeptides et acides nucleiques les codant
IL141535A0 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001249394A1 (en) Secreted proteins and polynucleotides encoding them
AU2001239889A1 (en) Polypeptides and nucleic acids encoding same
KR100514265B1 (en) Secreted and Transmembrane polypeptides and Nucleic Acids Encoding the Same
AU1453601A (en) Novel polypeptides and nucleic acids encoding same
AU2001234896A1 (en) Novel polypeptides and nucleic acids encoding same
KR100473125B1 (en) Secreted and Transmembrane polypeptides and Nucleic Acids Encoding the Same
AU5152700A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100528420B1 (en) Secreted and Transmembrane polypeptides and Nucleic Acids Encoding the Same
KR100473124B1 (en) Secreted and Transmembrane polypeptides and Nucleic Acids Encoding the Same
WO2002032961A8 (fr) Nouveaux polypeptides et acides nucleiques les codant
AU2001234627A1 (en) Novel polypeptides and nucleic acids encoding same
AU2001289282A1 (en) Secreted proteins and polynucleotides encoding them
IL142673A0 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase